{"id":"darbepoetin-alfa-injection","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"10-20","effect":"Headache"},{"rate":"5-15","effect":"Arthralgia"},{"rate":"5-10","effect":"Myalgia"},{"rate":"variable","effect":"Thrombotic events (stroke, MI, DVT)"},{"rate":"rare","effect":"Pure red cell aplasia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Darbepoetin alfa is a recombinant human erythropoietin analog with a longer half-life than epoetin alfa due to additional carbohydrate chains. It binds to erythropoietin receptors on erythroid progenitor cells in the bone marrow, promoting their proliferation, differentiation, and maturation into mature red blood cells. This mechanism increases hemoglobin levels and reduces the need for blood transfusions in patients with anemia.","oneSentence":"Darbepoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to stimulate red blood cell production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:41.138Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Chemotherapy-induced anemia in cancer patients"},{"name":"Anemia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy"}]},"trialDetails":[{"nctId":"NCT07096297","phase":"PHASE2","title":"Luspatercept + Darbepoetin in MDS","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-12-16","conditions":"MDS (Myelodysplastic Syndrome)","enrollment":60},{"nctId":"NCT05340465","phase":"PHASE2","title":"Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-11-27","conditions":"Prematurity, Iron-deficiency, Iron Deficiency Anemia","enrollment":120},{"nctId":"NCT04798339","phase":"PHASE1, PHASE2","title":"Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-03-30","conditions":"Myelodysplastic Syndromes","enrollment":13},{"nctId":"NCT07119372","phase":"PHASE3","title":"Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis","status":"RECRUITING","sponsor":"Biocad","startDate":"2025-03-01","conditions":"Anemia, Chronic Kidney Disease, Chronic Kidney Disease Patients on Hemodialysis","enrollment":228},{"nctId":"NCT02278341","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-11-21","conditions":"Anemia, End Stage Renal Disease (ESRD)","enrollment":838},{"nctId":"NCT02021318","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-03-12","conditions":"Anemia in Chronic Kidney Disease in Non-dialysis Patients","enrollment":616},{"nctId":"NCT06466785","phase":"PHASE3","title":"A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis","status":"RECRUITING","sponsor":"Genexine, Inc.","startDate":"2024-01-25","conditions":"Anemia of Chronic Kidney Disease","enrollment":429},{"nctId":"NCT02876835","phase":"PHASE3","title":"Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-27","conditions":"Anaemia","enrollment":3872},{"nctId":"NCT03446612","phase":"PHASE2","title":"Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-01-10","conditions":"Anaemia","enrollment":6},{"nctId":"NCT03457701","phase":"PHASE2","title":"Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-07-30","conditions":"Anaemia","enrollment":15},{"nctId":"NCT05864261","phase":"PHASE4","title":"Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male Volunteers","status":"COMPLETED","sponsor":"Yi Fang","startDate":"2023-05-15","conditions":"Renal Anemia","enrollment":74},{"nctId":"NCT00146562","phase":"PHASE2","title":"Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer","status":"COMPLETED","sponsor":"Harold J. Burstein, MD, PhD","startDate":"2003-07","conditions":"Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer","enrollment":135},{"nctId":"NCT05768997","phase":"PHASE3","title":"High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2023-03-01","conditions":"Anemia","enrollment":312},{"nctId":"NCT00436748","phase":"PHASE3","title":"Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease","status":"TERMINATED","sponsor":"Amgen","startDate":"2008-09-16","conditions":"Anemia, Chronic Kidney Disease, Kidney Disease","enrollment":116},{"nctId":"NCT00358215","phase":"PHASE3","title":"RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-06-01","conditions":"Heart Failure, Anemia, Cardiovascular Disease","enrollment":2278},{"nctId":"NCT01652872","phase":"PHASE3","title":"Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-07-30","conditions":"Anemia in Chronic Kidney Disease Patients Not on Dialysis","enrollment":756},{"nctId":"NCT04012957","phase":"PHASE3","title":"Desidustat in the Treatment of Anemia in CKD","status":"COMPLETED","sponsor":"Zydus Lifesciences Limited","startDate":"2019-07-20","conditions":"Chronic Kidney Disease Stage 3, Anemia, Chronic Kidney Disease Stage 4","enrollment":588},{"nctId":"NCT03029208","phase":"PHASE3","title":"Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-05-11","conditions":"Anaemia","enrollment":312},{"nctId":"NCT00717821","phase":"PHASE3","title":"A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-08","conditions":"Anemia","enrollment":421},{"nctId":"NCT03543657","phase":"PHASE3","title":"Maintenance Treatment of Renal Anemia in Dialysis Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-06-23","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":229},{"nctId":"NCT02969655","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-11-21","conditions":"Anaemia","enrollment":271},{"nctId":"NCT00058422","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-02-10","conditions":"Lymphoma","enrollment":65},{"nctId":"NCT03992066","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2019-05-28","conditions":"Anemia Associated With Chronic Kidney Disease","enrollment":46},{"nctId":"NCT02506868","phase":"PHASE3","title":"Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients","status":"COMPLETED","sponsor":"Biocad","startDate":"2015-08-08","conditions":"Chronic Kidney Disease, End Stage Renal Failure on Dialysis, Anemia","enrollment":196},{"nctId":"NCT03693950","phase":"PHASE1","title":"The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers","status":"COMPLETED","sponsor":"Biocad","startDate":"2017-03-28","conditions":"Healthy","enrollment":57},{"nctId":"NCT00334737","phase":"PHASE2","title":"Darbepoetin Administration to Preterm Infants","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2006-06","conditions":"Infant, Newborn","enrollment":102},{"nctId":"NCT03776032","phase":"PHASE3","title":"A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"1999-09-14","conditions":"Anemia","enrollment":320},{"nctId":"NCT03542916","phase":"PHASE1","title":"Pharmacokinetics Study of CJ-40001 and NESP® After Single Dose Administration in Health Male Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2014-10","conditions":"Healthy Subjects","enrollment":56},{"nctId":"NCT01362140","phase":"PHASE3","title":"Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-12-21","conditions":"MDS","enrollment":147},{"nctId":"NCT02055482","phase":"PHASE2","title":"Long-term Pre-dialysis Extension in Europe and Asia Pacific","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-06-24","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":166},{"nctId":"NCT02044653","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Genexine, Inc.","startDate":"2014-04-15","conditions":"Anemia, Chronic Kidney Disease","enrollment":257},{"nctId":"NCT00717366","phase":"PHASE2","title":"Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-07","conditions":"Renal Anemia","enrollment":64},{"nctId":"NCT00647998","phase":"PHASE2","title":"The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding Trial","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2008-01","conditions":"Spinal Ischemia, Stroke, Neuroprotection","enrollment":18},{"nctId":"NCT00377481","phase":"PHASE4","title":"COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-09","conditions":"Anemia","enrollment":48},{"nctId":"NCT00559273","phase":"PHASE3","title":"A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-12","conditions":"Renal Anemia, Chronic","enrollment":307},{"nctId":"NCT02506881","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers","status":"COMPLETED","sponsor":"Biocad","startDate":"2013-03","conditions":"Healthy","enrollment":74},{"nctId":"NCT01043991","phase":"PHASE3","title":"Intracoronary Injection of Epo After Myocardial Infarct \"Intra-CO-EpoMI\"","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2008-12","conditions":"Acute Myocardial Infarct","enrollment":54},{"nctId":"NCT00544232","phase":"PHASE3","title":"Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2002-08","conditions":"Breast Cancer","enrollment":720},{"nctId":"NCT00364845","phase":"PHASE3","title":"STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients","status":"TERMINATED","sponsor":"Amgen","startDate":"2006-09","conditions":"Anemia, Chronic Kidney Disease","enrollment":51},{"nctId":"NCT00401544","phase":"PHASE2","title":"Darbepoetin Alfa With or Without Intravenous (IV) Iron","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-12","conditions":"Anemia, Non-Myeloid Malignancies","enrollment":243},{"nctId":"NCT00579046","phase":"PHASE3","title":"Study of Erythropoietin to Treat Anemia Complicating Chronic Obstructive Pulmonary Disease","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-11","conditions":"Anemia, Chronic Obstructive Pulmonary Disease","enrollment":""},{"nctId":"NCT00213291","phase":"PHASE3","title":"Darbepoetin Treatment of Anemia in Children With Chronic Renal Failure","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2005-04","conditions":"Kidney Failure, Chronic","enrollment":40},{"nctId":"NCT00035607","phase":"PHASE2","title":"Chemotherapy Related Anemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2001-12","conditions":"Anemia, Non-Myeloid Malignancies","enrollment":120},{"nctId":"NCT00540384","phase":"PHASE1, PHASE2","title":"Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"1999-07","conditions":"Anemia, Solid Tumors","enrollment":405},{"nctId":"NCT00598273","phase":"PHASE3","title":"Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis","status":"COMPLETED","sponsor":"Affymax","startDate":"2007-10","conditions":"Chronic Renal Failure, Chronic Kidney Disease, Anemia","enrollment":490},{"nctId":"NCT00598442","phase":"PHASE3","title":"Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis","status":"COMPLETED","sponsor":"Affymax","startDate":"2007-11","conditions":"Chronic Renal Failure, Chronic Kidney Disease, Anemia","enrollment":493},{"nctId":"NCT00752609","phase":"PHASE2","title":"Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-09","conditions":"Anemia","enrollment":102},{"nctId":"NCT00090753","phase":"PHASE3","title":"A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-10","conditions":"Anemia","enrollment":1228},{"nctId":"NCT00442702","phase":"PHASE3","title":"A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-09","conditions":"Anemia","enrollment":228},{"nctId":"NCT00454246","phase":"PHASE3","title":"A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-04","conditions":"Anemia","enrollment":111},{"nctId":"NCT00661999","phase":"PHASE3","title":"Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2006-01","conditions":"Anemia, Leukemia, Lymphoma","enrollment":502},{"nctId":"NCT00907608","phase":"NA","title":"A Proof-of-Concept Study of Darbepoetin Alfa in Partial Correction of Anemia in Chinese With Diabetic Nephropathy","status":"TERMINATED","sponsor":"Chinese University of Hong Kong","startDate":"2007-12","conditions":"Diabetes Mellitus, Chronic Kidney Disease, Anemia","enrollment":16},{"nctId":"NCT00036023","phase":"PHASE2","title":"Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Lymphoma, Breast Neoplasms, Lung Neoplasms","enrollment":""},{"nctId":"NCT00234143","phase":"PHASE2, PHASE3","title":"Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)","status":"UNKNOWN","sponsor":"St. Bartholomew's Hospital","startDate":"2004-10","conditions":"Myelodysplastic Syndromes","enrollment":360}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["aranesp","Darbe"],"phase":"phase_3","status":"active","brandName":"Darbepoetin Alfa Injection","genericName":"Darbepoetin Alfa Injection","companyName":"University of New Mexico","companyId":"university-of-new-mexico","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Darbepoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to stimulate red blood cell production. Used for Anemia associated with chronic kidney disease, Chemotherapy-induced anemia in cancer patients, Anemia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}